A kind of anti-human tslp monoclonal antibody and application thereof

A monoclonal antibody and thymus technology, applied in the direction of antibody, anti-animal/human immunoglobulin, anti-cytokine/lymphokine/interferon immunoglobulin, etc., can solve incurable asthma, atopic dermatitis and allergy Sexual rhinitis and other problems, to achieve good clinical results

Active Publication Date: 2022-05-13
QYUNS THERAPEUTICS CO LTD
View PDF44 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, there is no cure for allergy-induced asthma, atopic dermatitis, and allergic rhinitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of anti-human tslp monoclonal antibody and application thereof
  • A kind of anti-human tslp monoclonal antibody and application thereof
  • A kind of anti-human tslp monoclonal antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Embodiment 1 Preparation of anti-human TSLP monoclonal antibody QX008N

[0083] Purchasing human thymic stromal lymphopoietin (hTSLP) from Shanghai Nearshore Technology Co., Ltd. for immunization of New Zealand rabbits, using B cell cloning technology to obtain antigen-binding specific antibody clones, and then screening for binding to human TSLP and having human TSLP inhibitory activity of monoclonal antibodies. The cell supernatant was detected by Binding ELISA and Blocking ELISA, and the target clone was selected. The above immunization and screening processes are entrusted to commercial companies.

[0084]Seven clones were selected for recombinant expression and sequenced. It has been determined that 8G2 has the best cell neutralizing activity. Therefore, the 8G2 clone was humanized. Use NCBI IgBlast to carry out homology comparison of human IgG germline sequence (Germline), select IGHV3-66*01 as the heavy chain CDR transplantation template, and clone the CDR re...

Embodiment 2

[0089] Embodiment 2 Equilibrium dissociation constant (K D ) determination

[0090] The affinity between QX008N(HZD8G2-57) and human TSLP was detected by Biacore T200, and all processes were carried out at 25°C. A commercial ProteinA chip was used to immobilize an appropriate amount of antibody by the capture method, so that the Rmax was around 50RU, and the capture flow rate was 10 μl / min. The antigen was serially diluted, the flow rate of the instrument was switched to 30 μl / min, and the concentration flowed through the reference channel and the channel of the immobilized antibody in order of concentration from low to high, and the buffer was used as a negative control. After each association and dissociation, the chip was regenerated with pH 1.5 glycine. Use the analysis software that comes with the instrument to select the 1:1 binding model in the Kinetics option for fitting, and calculate the binding rate constant k of the antibody a , the dissociation rate constant k ...

Embodiment 3

[0095] Example 3QX008N and Tezepelumab neutralize human TSLP-induced SW756-STAT5-Luciferase reporter cell STAT5 phosphorylation activity

[0096] The SW756-STAT5-Luciferase reporter gene cell line was used to measure QX008N antagonizing the phosphorylation activity of intracellular signal molecule STAT5 mediated by human TSLP through TSLPR-IL-7R: the cells in the culture medium were divided into 4×10 cells per well 4 Cells were added to 96 wells and then incubated at 37°C and 5% CO 2 conditions overnight. Add the pre-incubated antibody and human TSLP mixture to the cells, where the final concentration of QX008N ranges from 0 to 50 ng / ml, the final concentration of Tezepelumab ranges from 0 to 400 ng / ml, and the final concentration of TSLP is 0.5 ng / ml. Then at 37 °C and 5% CO 2 Cultivate under conditions for 24 hours, discard the cell culture supernatant, add 120 μl ONE-Glo-Luciferase Reagent detection reagent to each well, and act for 30 minutes, take 100 μl from each well ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This application provides an anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody and its application. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody of the present application comprises three heavy chain complementarity determining regions (CDR‑H1, CDR‑H2 and CDR‑H3) and three light chain complementarity determining regions (CDR‑L1 , CDR‑L2 and CDR‑L3), wherein, (a) the amino acid sequence of CDR‑H1 is shown in SEQ ID NO: 1; (b) the amino acid sequence of CDR‑H2 is shown in SEQ ID NO: 2; (c ) The amino acid sequence of CDR‑H3 is shown in SEQ ID NO: 3; (d) the amino acid sequence of CDR‑L1 is shown in SEQ ID NO: 4; (e) the amino acid sequence of CDR‑L2 is shown in SEQ ID NO: 5 and (f) the amino acid sequence of CDR-L3 is shown in SEQ ID NO:6. The anti-human thymus stromal lymphopoietin (TSLP) monoclonal antibody, compared with the anti-human TSLP monoclonal antibody Tezepelumab (expressed and prepared according to the sequence disclosed in the patent), has comparable affinity for binding human TSLP, and is in the cell level. It is more active than Tezepelumab and is expected to show good clinical effects in the prevention and treatment of related diseases.

Description

technical field [0001] This application relates to the field of antibody medicine. Specifically, the present application relates to monoclonal antibodies against human thymic stromal lymphopoietin (TSLP) and applications thereof. Background technique [0002] Cytokines and immune cells mediate specific physiological mechanisms or pathways, eg, pathways leading to a variety of inflammatory disorders. Human thymic stromal lymphopoietin (TSLP) is an IL-7 cytokine produced by human epithelial cells. It promotes B cell differentiation and is also able to co-stimulate thymocytes and mature T cells. TSLP binds to human CD11c + Specific heterodimeric receptors on dendritic cells (DC). This receptor heterodimer consists of a heterodimer of a common gamma-like receptor chain (TSLP receptor; TSLPR) and an IL-7R-alpha chain. See eg Tonozuka et al., Cytogenet. Cell Genet. 93:23-25, 2001; Pandey et al., Nat. Immunol. 1:59-64, 2000; L.S. Park et al., J.Exp.Med. Reche et al., J. Immun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K16/24A61K39/395A61P37/08A61P11/06A61P17/00A61P11/02A61P1/00A61P27/14
CPCC07K16/244A61P37/08A61P11/06A61P17/00A61P11/02A61P1/00A61P27/14C07K2317/565C07K2317/56C07K2317/92C07K2317/76
Inventor 裘霁宛孔永陈卫乔怀耀吴亦亮陈涛梁立业周毅
Owner QYUNS THERAPEUTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap